Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Projected CAGR for the Colorectal Cancer Molecular Diagnostics Market Size from 2025 to 2034?
The market size of molecular diagnostics for colorectal cancer has seen robust growth in recent times. Its trajectory is set to soar from $2.56 billion in 2024 to $2.76 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.9%. This growth during the historical period is owed to multiple factors such as an upsurge in colorectal cancer instances, amplified awareness and screening initiatives, heightened focus on personalized treatment, and government measures to moderate cancer.
Expectations are high for robust expansion in the colorectal cancer molecular diagnostics market in the coming years, with projections for a growth to$3.79 billion by 2029, at a Compound Annual Growth Rate (CAGR) of 8.3%. This anticipated growth during the forecast period can be associated with factors such as an aging demographic and augmented risk factors, the incorporation of genomic data into routine clinical practices, an upsurge in precision medicine methodologies, as well as global engagement in cancer research collaborations. Emerging trends anticipated during the forecast period includes a growing focus on early detection biomarkers, the incorporation of Artificial Intelligence (AI) in data analysis, the rise in Circulating Tumor DNA (CTDNA) examinations, the broadening of companion diagnostics for targeted therapies and an emphasis on immunotherapy biomarkers.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13120&type=smp
What Are the Core Growth Drivers Propelling the Colorectal Cancer Molecular Diagnostics Market Forward?
The growth of the colorectal cancer molecular diagnostic market is likely to be fueled by the growing prevalence of inflammatory bowel diseases (IBD). IBDs are long-lasting gastrointestinal ailments characterized by inflammation of the digestive tract, predominantly impacting the colon and rectum, and displaying symptoms such as abdominal discomfort, diarrhea, and weight loss. These are typically managed via medication, lifestyle alterations, and occasionally, surgery. The rising prevalence of IBD necessitates the need for precise, effective, and cutting-edge diagnostic options as colorectal cancer (CRC) systemic therapy largely depends on the outcomes from molecular evaluation of the tumor. For instance, a study by Crohn’s & Colitis UK in 2022 reported that an estimated 500,000 people in the U.K live with IBD—almost twice the previous estimates. according to a statement by the UK Parliament in April 2024. Therefore, the increasing cases of IBD are expected to provide a significant boost to the colorectal cancer molecular diagnostic market.
What Segment Types Define the Colorectal Cancer Molecular Diagnostics Market Structure?
The colorectal cancer molecular diagnosticsmarket covered in this report is segmented –
1) By Type: Instruments; Reagents And Kits; Services
2) By Technology: Polymerase Chain Reaction (PCR); Sequencing; Mass Spectrometry; Transcription Mediated Amplification; Chips And Microarrays; Isothermal Nucleic Acid Amplification Technology (INAAT)
3) By End Users: Hospitals; Ambulatory Surgical Centers; Diagnostic Laboratories; Homecare Settings
Subsegments:
1) By Instruments: PCR Machines; Sequencers; Microarrays
2) By Reagents And Kits: DNA Or RNA Extraction Kits; Assay Kits; Reagent Packs
3) By Services: Diagnostic Testing Services; Genetic Testing Services; Consultation Services
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13120&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Colorectal Cancer Molecular Diagnostics Market?
North America was the largest region in the colorectal cancer molecular diagnostics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colorectal cancer molecular diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Which Emerging Trends that Are Influencing theColorectal Cancer Molecular Diagnostics Industry Evolution?
Leading enterprises in the colorectal cancer molecular diagnostic market are striving to create innovative molecular diagnostics and personalized medical solutions, such as the shield blood test method, to detect colorectal cancer at a more manageable, earlier stage. The Shield Blood Test was initially developed to pinpoint early-stage colorectal cancer (CRC). For instance, in May 2022, Guardant Health, a biotech firm based in the United States that provides molecular diagnostic products for oncology, introduced its Shield Blood Test. This novel shield test offers a user-friendly screening alternative, requiring only a basic blood draw, to overcome the reluctance of patients to undergo screening. The test exhibited a 91% sensitivity in identifying colorectal cancer and a 20% sensitivity for advanced adenomas, while the specificity was recorded at 92%. By analyzing data from a wide variety of cohorts, including over 2,000 colorectal cancer patients, 357 advanced adenoma patients, and 3,757 normal individuals, the Shield test can detect early signals of colorectal cancer in the blood.
View the full report here:
What Is the Definition of the Colorectal Cancer Molecular Diagnostics Market?
Colorectal cancer, also known as colon cancer or rectal cancer, is a malignant tumor that develops in the colon (the large intestine) or the rectum (the final portion of the digestive tract just before the anus). It is a type of cancer that arises from the inner lining of these parts of the gastrointestinal system. Colorectal cancer molecular diagnostics uses advanced techniques to identify specific genetic mutations, alterations, and biomarkers that play a role in the development, progression, and treatment response of colorectal cancer.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13120
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model